INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 06 (2025)
139
THE NEUROBIOLOGY OF DEPRESSION AND NEW TREATMENT STRATEGIES:
UNLOCKING THE MIND’S HIDDEN BATTLES
Tulayev Bobur Zoyir ugli
5rd year student, Faculty of Pediatrics
Samarkand State Medical University
Pardayeva Azizabonu Ulug'bek qizi
3rd-year student, Faculty of General Medicine
Samarkand State Medical University
Asadbek G'aniyev Ulug'bekovich
Eshmuradov Quyoshbek Sanjar ugli
4th-year students, Faculty of General Medicine
Samarkand State Medical University
Beknazarov Shahobiddin Fazliddin ugli
4th-year student, Faculty of Pediatrics
Samarkand State Medical University
Abstract:
Depression is a leading cause of disability worldwide, affecting more than 280 million
people. Traditionally considered a psychological disorder, recent advancements in neuroscience
have revealed complex neurobiological underpinnings, including disruptions in neurotransmitter
systems, neuroinflammation, and structural brain changes. This article explores the current
understanding of the neurobiology of depression and evaluates innovative treatment strategies,
such as ketamine, transcranial magnetic stimulation, and psilocybin-based therapy. By bridging
classical approaches with novel discoveries, this review aims to shed light on the future direction
of depression management.
Keywords:
Depression, neurobiology, BDNF, HPA axis, neuroinflammation, ketamine,
psilocybin, transcranial magnetic stimulation, treatment-resistant depression, mental health, brain
plasticity, monoamine hypothesis, personalized psychiatry.
1. Introduction
Depression, or Major Depressive Disorder (MDD), is not just prolonged sadness—it is a
multifaceted condition with severe psychological, social, and physiological consequences.
According to the World Health Organization (WHO), depression is the leading contributor to
global disability, particularly among adolescents and women. Despite decades of research and the
availability of antidepressants, treatment-resistant depression remains common. Understanding
the neurobiological basis of depression is crucial to developing more effective and rapid-acting
treatments.
2. The Neurobiology of Depression
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 06 (2025)
140
2.1 Monoamine Hypothesis
Historically, depression has been associated with deficiencies in monoamine neurotransmitters,
particularly serotonin (5-HT), norepinephrine (NE), and dopamine (DA). Selective serotonin
reuptake inhibitors (SSRIs) and other antidepressants target these systems. However, their delayed
onset and limited efficacy in some patients suggest deeper mechanisms at play.
2.2 Neuroplasticity and BDNF
Brain-Derived Neurotrophic Factor (BDNF) is essential for neuronal survival and synaptic
plasticity. In depressed individuals, BDNF levels—especially in the hippocampus and prefrontal
cortex—are reduced. Antidepressants have been shown to increase BDNF expression, promoting
neurogenesis and cognitive restoration. Animal models demonstrate that chronic stress
downregulates BDNF, while physical activity and enriched environments can upregulate it.
2.3 HPA Axis Dysregulation
The hypothalamic-pituitary-adrenal (HPA) axis, responsible for the div’s stress response, is
frequently overactive in depressed individuals. This hyperactivity results in elevated cortisol
levels, which have neurotoxic effects on the hippocampus and prefrontal cortex. Chronic cortisol
elevation impairs neurogenesis and reduces dendritic branching, contributing to cognitive and
emotional symptoms of depressio
2.4 Neuroinflammation
Growing evidence suggests that depression is associated with systemic inflammation. Elevated
levels of cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-
reactive protein (CRP) have been found in depressed patients. These cytokines may disrupt
monoamine metabolism, reduce BDNF levels, and affect glutamatergic neurotransmission.
Moreover, microglial activation in the brain can exacerbate neuronal damage and contribute to the
chronicity of depression.
2.5 Structural and Functional Brain Changes
Neuroimaging studies using MRI and PET scans have revealed consistent changes in brain
structure and function in depressed individuals. These include:
Reduced hippocampal volume, affecting memory and emotional regulation
Decreased activity in the dorsolateral prefrontal cortex (DLPFC), linked to executive dysfunction.
Increased activity in the amygdala, contributing to heightened emotional reactivity.
Disrupted connectivity in the default mode network (DMN), associated with rumination
Longitudinal studies suggest that effective treatment may partially reverse some of these changes.
3. Current and Emerging Treatments
3.1 Traditional Pharmacotherapy
While SSRIs and SNRIs remain the standard of care, their limitations include delayed onset of
action and side effects such as sexual dysfunction, weight gain, and emotional blunting.
Augmentation strategies using atypical antipsychotics (e.g., aripiprazole, quetiapine) and mood
stabilizers (e.g., lithium) are used in treatment-resistant cases.
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 06 (2025)
141
3.2 Rapid-Acting Antidepressants: Ketamine and Esketamine
Ketamine, a dissociative anesthetic, acts as an NMDA receptor antagonist. It induces rapid
antidepressant effects by enhancing synaptogenesis via mTOR signaling pathways and increasing
BDNF release. Clinical trials show significant improvement in depressive symptoms within hours,
making it especially valuable in suicidal patients. Esketamine, the S-enantiomer of ketamine, has
been approved by the FDA for treatment-resistant depression.
3.3 Brain Stimulation Techniques
Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to
stimulate specific brain regions. Repetitive TMS (rTMS) applied to the left DLPFC has shown
efficacy in patients unresponsive to medications. Electroconvulsive therapy (ECT), although
stigmatized, remains one of the most effective treatments for severe or psychotic depression.
Newer techniques like transcranial direct current stimulation (tDCS) are being explored for home-
based use.
3.4 Psychedelic-Assisted Therapy
Psychedelics such as psilocybin and MDMA have demonstrated profound therapeutic effects in
clinical trials. Psilocybin promotes increased connectivity in brain networks and induces
transformative emotional experiences that help patients reprocess trauma and depressive thought
patterns. Unlike traditional antidepressants, their effects can be long-lasting after just one or two
sessions, especially when combined with psychotherapy.
3.5 Psychotherapy and Digital Interventions
Cognitive Behavioral Therapy (CBT) remains a cornerstone in depression treatment. Newer
modalities such as Acceptance and Commitment Therapy (ACT) and Dialectical Behavior
Therapy (DBT) are increasingly used. Digital platforms offering CBT modules, virtual therapists,
and mood-tracking apps have enhanced accessibility and adherence, particularly during the
COVID-19 pandemic.
3.6 Lifestyle and Nutritional Interventions
Lifestyle factors play a significant role in depression. Regular physical activity increases
endorphins and BDNF levels. Diets such as the Mediterranean diet, rich in omega-3 fatty acids,
antioxidants, and fiber, have been associated with reduced depression risk. Emerging fields like
nutritional psychiatry explore the gut-brain axis, suggesting that probiotics and prebiotics may
influence mood through modulation of the microbiome.
3.7 Anti-inflammatory and Novel Agents
Several trials have tested the efficacy of anti-inflammatory agents, such as aspirin, celecoxib, and
minocycline, as adjuncts to antidepressants. Additionally, compounds like N-acetylcysteine (NAC)
and cannabidiol (CBD) are being investigated for their neuroprotective and mood-stabilizing
effects.
4. Integrative and Personalized Psychiatry
Precision medicine aims to tailor treatment based on individual genetic, biological, and
psychosocial profiles. Pharmacogenetic testing helps identify patients likely to benefit from
specific antidepressants, reducing trial-and-error prescribing. Multimodal approaches that
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 06 (2025)
142
combine pharmacological, psychological, and lifestyle interventions offer the most promise in
treating complex cases.
5. Conclusion
Depression is a biologically and psychologically intricate disorder. Advances in neuroimaging,
molecular biology, and psychopharmacology have transformed our understanding and treatment
of depression. While traditional therapies remain essential, the emergence of rapid-acting
antidepressants, brain stimulation, and psychedelics mark a paradigm shift. Moving forward,
integrating evidence-based innovations with compassionate, personalized care holds the key to
alleviating the burden of depression for millions.
References
1. World Health Organization. (2023). Depression. https://www.who.int/news-room/fact-
sheets/detail/depression
2. Duman, R.S., & Aghajanian, G.K. (2012). Synaptic dysfunction in depression: potential
therapeutic targets. Science, 338(6103), 68–72.
3. Krystal, J.H. et al. (2019). Ketamine and rapid-acting antidepressants: a new era in psychiatry.
Nature Reviews Drug Discovery, 18(3), 145–162.
4. Carhart-Harris, R.L. et al. (2021). Trial of psilocybin versus escitalopram for depression. NEJM,
384(15), 1402–1411.
5. Otte, C. et al. (2016). Major depressive disorder. Nature Reviews Disease Primers, 2(1), 1–20.
6. Malhi, G.S., Mann, J.J. (2018). Depression. The Lancet, 392(10161), 2299–2312.
7. Felger, J.C., & Miller, A.H. (2012). Cytokine effects on the basal ganglia and dopamine
function. Neuropsychopharmacology, 37(1), 137–156.
8. Caspi, A., et al. (2003). Influence of life stress on depression: moderation by a polymorphism
in the 5-HTT gene. Science, 301(5631), 386–39.
9. Gibb, B.E., & Alloy, L.B. (2006). A prospective test of the hopelessness theory of depression.
Cognitive Therapy and Research, 30(6), 763–783.
